Founded in 2009, UpStart Ventures focuses on investing in Series B rounds and has a unique investment strategy that combines idea generation, science discovery, seed stage investing, venture judgment, and company management. Their first fund, UpStart Life Sciences Capital, primarily invests in seed and early-stage healthcare companies with breakthrough technologies from research universities in Utah and neighboring states. They specifically target medical devices, drug delivery systems, diagnostics, and biopharma products and platforms. UpStart Ventures has made successful investments in Sera Prognostics, a company developing blood tests for predicting preterm birth and other pregnancy complications.